1. Limaiem F, Sticco KL. Cancer, chondrosarcoma. 2019. Available at https://www.ncbi.nlm.nih.gov/books/NBK538132/
3. Lakshmanan P. Chondrosarcoma. Available at https://emedicine.medscape.com/article/1258236-overview#showall
6. Anggreani I, Kodrat E, Wuyung PE. Peran Isocitrate Dehydrogenase (IDH) pada Kondrosarkoma. Pratista Patologi. 2019;6(2):1-14.
26. NCCN Clinical Practice Guideline in Oncology. Bone Cancer. Version 1. 2019. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
27. Mermerkaya MU, Bekmez S, Karaaslan F, et al. Intralesional curettage and cementation for low-grade chondrosarcoma of long bones: retrospective study and literature review. World J Surg Oncol. 2014;12(336):1-5.
28. Omlor GW, Lohnherr V, Lange J, et al. Enchondromas and atypical cartilaginous tumors at the proximal humerus treated with intralesional resection and bone cement filling with or without osteosynthesis: retrospective analysis of 42 cases with 6 years mean follow-up. World Journal of Surgical Oncology. 2018;16(1):1-9.
29. Kim CY, Collier CD, Liu RW, et al. Are Limb-sparing Surgical Resections Comparable to Amputation for Patients with Pelvic Chondrosarcoma? A Case-control, Propensity Score-matched Analysis of the National Cancer Database. Clinical Orthopaedics and Related Research. 2019;477(3):596–605.
30. Wagner A, Venbrocks RA, Fuhrmann RA. Chondrosarcoma of the Calcaneus: Amputation or Resection with Limb Preservation: A Case Report. Foot & Ankle International. 2007.28(10):1090-1094.
31. Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018;29(4):79–95.
32. Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer. 2007;43(14):2060-5.
33. Li L, Paz AC, Wilky BA, et al. Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the onco-metabolite 2-hydroxyglutarate in human chondrosarcoma cells. PLoS One. 2015; 10:1-19.
34. Suijker J, Oosting J, Koornneef A, Struys EA, Gajja SS, Schaap FG, et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondroma cell lines. Oncotarget. 2015; 6:12505-19.